• Citer

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

par Dieli, F;Vermijlen, David ;Fulfaro, Fabio;Caccamo, N;Meraviglia, S;Cicero, G;Roberts, Andrew;Buccheri, S;D'Asaro, M;Gebbia, Nicola;Salerno, Alfredo;Eberl, M;Hayday, A C
Référence Cancer research, 67, 15, page (7450-7457)
Publication Publié, 2007-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
Auteur:	Dieli, F; Vermijlen, David; Fulfaro, Fabio; Caccamo, N; Meraviglia, S; Cicero, G; Roberts, Andrew; Buccheri, S; D'Asaro, M; Gebbia, Nicola; Salerno, Alfredo; Eberl, M; Hayday, A C
Informations sur la publication:	Cancer research, 67, 15, page (7450-7457)
Statut de publication:	Publié, 2007-08
Sujet CREF:	Immunologie
MeSH keywords:	Aged
	Aged, 80 and over
	Antineoplastic Agents -- therapeutic use
	Bone Density Conservation Agents -- therapeutic use
	Diphosphonates -- therapeutic use
	Dose-Response Relationship, Drug
	Drug Therapy, Combination
	Feasibility Studies
	Humans
	Imidazoles -- therapeutic use
	Immunotherapy -- methods
	Interleukin-2 -- therapeutic use
	Lymphocyte Activation -- drug effects
	Male
	Middle Aged
	Neoplasms, Hormone-Dependent -- drug therapy
	Prostatic Neoplasms -- drug therapy
	Receptors, Antigen, T-Cell, gamma-delta
	Remission Induction
	Salvage Therapy
	T-Lymphocytes -- cytology -- drug effects -- immunology
	Treatment Outcome
Note générale:	Journal Article
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0008-5472
	info:doi/10.1158/0008-5472.CAN-07-0199
	info:pii/67/15/7450
	info:scp/34547638252
	info:pmid/17671215